Oxford BioDynamics Plc (LON:OBD – Get Free Report) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 0.14 and traded as low as GBX 0.10. Oxford BioDynamics shares last traded at GBX 0.11, with a volume of 25,940,104 shares changing hands.
Oxford BioDynamics Trading Down 9.9%
The stock has a market capitalization of £4.29 million, a P/E ratio of -0.50 and a beta of 0.42. The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The business has a 50-day moving average price of GBX 0.14 and a two-hundred day moving average price of GBX 0.20.
Oxford BioDynamics (LON:OBD – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) EPS for the quarter. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.
About Oxford BioDynamics
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
See Also
- Five stocks we like better than Oxford BioDynamics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
